CriticalCentrally acting sympathomimetics×Selective serotonin reuptake inhibitor (SSRI)
Updated · Methodology
Mechanism
The liver breaks down atomoxetine mainly through the enzyme CYP2D6, and paroxetine is a strong inhibitor of this enzyme (paroxetine and atomoxetine labels, US Food and Drug Administration, FDA). With paroxetine 20 mg daily, atomoxetine exposure rose 6.5-fold and its peak concentration about 3- to 4-fold (atomoxetine FDA label). Paroxetine raises the concentration of CYP2D6 substrates that prolong the corrected QT interval (QTc), which may cause a greater QTc increase, torsade de pointes, other serious arrhythmias and sudden death (paroxetine FDA label). Atomoxetine is a CYP2D6 substrate, and QT prolongation is among its adverse reactions. In a dedicated study, QTc rose slightly as atomoxetine concentration increased (atomoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Serotonin syndrome has been reported in people who took atomoxetine with selective serotonin reuptake inhibitors (SSRIs), the group paroxetine belongs to (atomoxetine SmPC, AEMPS).
Symptoms
People whose CYP2D6 does not work (poor metabolizers) reach atomoxetine exposures similar to those seen with a strong inhibitor of this enzyme such as paroxetine (atomoxetine label, US Food and Drug Administration, FDA). Compared with adult extensive metabolizers, whose CYP2D6 works normally, adult poor metabolizers had dry mouth in 34.5% versus 17.4%, insomnia in 19.2% versus 11.3%, erectile dysfunction in 20.9% versus 8.9% and urinary retention in 5.9% versus 1.2%. In children, decreased appetite, insomnia, tremor and fainting were also more common in poor metabolizers (atomoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Heart rate rose more in adult poor metabolizers than in other metabolizer types, on average by 11 versus 7.5 beats per minute (atomoxetine FDA label). QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes causes palpitations, dizziness and fainting. Serotonin syndrome causes agitation, confusion, fast heart rate, labile blood pressure, sweating, fever, tremor, muscle rigidity, muscle jerks, nausea, vomiting and diarrhoea (paroxetine FDA label).
Management
The combination is contraindicated. The US Food and Drug Administration (FDA) paroxetine label forbids its use with CYP2D6 substrates that prolong the QT interval, and atomoxetine meets both conditions (paroxetine FDA label; atomoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The SmPCs are softer: they ask for caution when combining paroxetine with drugs that prolong QT and atomoxetine with CYP2D6 inhibitors (paroxetine and atomoxetine SmPCs, AEMPS). If the patient still takes both drugs, the atomoxetine FDA label keeps the usual starting, target and maximum doses. Raise the dose no sooner than after 4 weeks, and only if symptoms of attention deficit hyperactivity disorder (ADHD) have not improved and the starting dose is well tolerated (atomoxetine FDA label). The atomoxetine SmPC allows a slower titration and a lower final dose. If paroxetine is started or stopped after the atomoxetine dose has been set, reassess response and tolerability (atomoxetine SmPC, AEMPS). Measure pulse and blood pressure before starting atomoxetine, after each dose change and at least every 6 months (atomoxetine SmPC, AEMPS). If serotonin syndrome appears, stop paroxetine and other serotonergic drugs at once and start symptomatic treatment (paroxetine FDA label). For atomoxetine, consider a lower dose or stopping it, depending on severity (atomoxetine SmPC, AEMPS). Use atomoxetine with caution together with selective serotonin reuptake inhibitors (SSRIs), which lower the seizure threshold (atomoxetine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Frosinor 20 mg (paroxetina) (2026)– AEMPS CIMA, Frosinor 20 mg comprimidos recubiertos con película, nº registro 59466, secciones 4.3, 4.4 y 4.5
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- FDA: STRATTERA (atomoxetine) prescribing information (2026)– FDA, DailyMed setid 309de576-c318-404a-bc15-660c2b1876fb (Eli Lilly), revisión 06/2026 (versión 69), secciones 2.5, 6.2, 7, 8.7, 12.2 y 12.3
- AEMPS: Ficha técnica: Atomoxetina (nº registro 82446), sección 4.5 (2026)– AEMPS, CIMA, nº registro 82446 (Atomoxetina Cinfa 80 mg), revisión 09/2026, secciones 4.4, 4.5, 4.8, 5.1 y 5.2
- FDA: Atomoxetine capsules (American Health Packaging) prescribing information (2026)– FDA, DailyMed setid 10d36b32-0202-4c03-8a1a-cd5d53f231e7 (American Health Packaging), revisión 06/2026 (versión 8), secciones 2.5 y 7.2